Literature DB >> 36268380

Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura: A case report.

Prem Shankar Chaurasiya1, Akash Khatri2, Shekhar Gurung3, Saurab Karki4, Sunil Shahi5, Laxmi Aryal6.   

Abstract

Introduction and importance: Thrombotic thrombocytopenic purpura (TTP) is a rare disease due to deficiency of ADAMTS13 which can present with anemia and thrombocytopenia. The study highlights the role of PLASMIC score in diagnosis and rituximab in the treatment of this condition. Case presentation: Herein, we report a case of 38 years old female who had presented with fever, irritability, and altered sensorium. On investigations, she had hemolytic anemia, and thrombocytopenia with peripheral blood smear showing occasional schistocytes and managed with steroids and plasma exchange. As her platelet, LDH, and a few other lab parameters failed to normalize and met the criteria of refractory TTP, hence she was started on 5 cycles of rituximab and her condition improved. Clinical discussion: Thrombotic thrombocytopenic purpura can be presumed based upon PLASMIC score where if the score is 5 or more while ADAMTS13 assay is required for confirmation. It is a life-threatening condition where treatment options include therapeutic plasma exchange (PEX), glucocorticoids, Rituximab, and caplacizumab. Rituximab is considered particularly in refractory cases.
Conclusion: Thrombotic thrombocytopenic purpura can lead to complications due to low platelet counts. Hence, early diagnosis and intervention are crucial to prevent such complications.
© 2022 The Authors.

Entities:  

Keywords:  Anemia; PLASMIC score; Rituximab; Thrombocytopenia; Thrombotic thrombocytopenic purpura

Year:  2022        PMID: 36268380      PMCID: PMC9577965          DOI: 10.1016/j.amsu.2022.104789

Source DB:  PubMed          Journal:  Ann Med Surg (Lond)        ISSN: 2049-0801


  11 in total

1.  The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines.

Authors:  Riaz A Agha; Thomas Franchi; Catrin Sohrabi; Ginimol Mathew; Ahmed Kerwan
Journal:  Int J Surg       Date:  2020-11-09       Impact factor: 6.071

2.  Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: A systematic review and meta-analysis.

Authors:  Koosha Paydary; Emma Banwell; Jiayi Tong; Yong Chen; Adam Cuker
Journal:  Transfusion       Date:  2020-08-05       Impact factor: 3.157

3.  Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.

Authors:  Antoine Froissart; Marc Buffet; Agnès Veyradier; Pascale Poullin; François Provôt; Sandrine Malot; Michael Schwarzinger; Lionel Galicier; Philippe Vanhille; Jean-Paul Vernant; Dominique Bordessoule; Bertrand Guidet; Elie Azoulay; Eric Mariotte; Eric Rondeau; Jean-Paul Mira; Alain Wynckel; Karine Clabault; Gabriel Choukroun; Claire Presne; Jacques Pourrat; Mohamed Hamidou; Paul Coppo
Journal:  Crit Care Med       Date:  2012-01       Impact factor: 7.598

4.  Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.

Authors:  M Scully; S Cataland; P Coppo; J de la Rubia; K D Friedman; J Kremer Hovinga; B Lämmle; M Matsumoto; K Pavenski; E Sadler; R Sarode; H Wu
Journal:  J Thromb Haemost       Date:  2017-01-30       Impact factor: 5.824

5.  Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.

Authors:  Eric Mariotte; Elie Azoulay; Lionel Galicier; Eric Rondeau; Fouzia Zouiti; Pierre Boisseau; Pascale Poullin; Emmanuel de Maistre; François Provôt; Yahsou Delmas; Pierre Perez; Ygal Benhamou; Alain Stepanian; Paul Coppo; Agnès Veyradier
Journal:  Lancet Haematol       Date:  2016-04-16       Impact factor: 18.959

6.  Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy.

Authors:  Yoshitaka Miyakawa; Kazunori Imada; Tatsuo Ichinohe; Kenji Nishio; Takayuki Abe; Mitsuru Murata; Yasunori Ueda; Yoshihiro Fujimura; Masanori Matsumoto; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2016-05-17       Impact factor: 2.490

7.  Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab.

Authors:  Jens Chemnitz; Andreas Draube; Christof Scheid; Peter Staib; Armin Schulz; Volker Diehl; Dietmar Söhngen
Journal:  Am J Hematol       Date:  2002-10       Impact factor: 10.047

Review 8.  Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature.

Authors:  Sushama Jasti; Thomas Coyle; Teresa Gentile; Lawrence Rosales; Bernard Poiesz
Journal:  J Clin Apher       Date:  2008       Impact factor: 2.821

Review 9.  Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management.

Authors:  Senthil Sukumar; Bernhard Lämmle; Spero R Cataland
Journal:  J Clin Med       Date:  2021-02-02       Impact factor: 4.241

Review 10.  Thrombotic thrombocytopenic purpura.

Authors:  Paul Knöbl
Journal:  Memo       Date:  2018-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.